Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Post by antoninuson Aug 04, 2010 2:48pm
438 Views
Post# 17321481

lux senior management

lux senior management

Founder-chief operating officer

Mr. Atwell served as Director of Transplantation for Roche within the U.S., where he was responsible for the launch and growth of CellCept® into the leading immunosuppressive within the U.S. Market. This growth was based on the ability to build a sustainable franchise based on market leadership, a robust clinical program, and strong community based programs

 

Founder- chief medical officer


Prior to joining Enzon, Dr. Anglade served as Medical Director and Team Leader at Roche Laboratories, Inc. in the areas of virology and transplantation marketing. While at Roche, Dr. Anglade led a diverse team in the development and implementation of post-marketing studies with a budget exceeding $15 million for its transplantation (CellCept
® and Zenapax®) and virology (Cytovene®) franchises

<< Previous
Bullboard Posts
Next >>